Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of Lazertinib versus Lazertinib plus bevacizumab in EGFR-mutant advanced NSCLC with smoking history
KCT0008295Phase 2Recruiting
- Sponsor
- Yuhan
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lazertinib, bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Yuhan. Started Jun 2023; status: recruiting.
02
Drugs
lazertinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0008295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008295.